Hints and tips:
...Livongo, which uses technology tools such as coaching to help patients manage chronic ailments like diabetes, only went public in July last year at $28 a share....
...Verily products like Onduo, a joint venture with Sanofi to create a diabetes management platform, might move closer to Google Health....
...A joint venture agreed with Sanofi in 2016 is aimed at improving diabetes care. These moves might not pay off....
...She added: “We’ve also done a lot of work on health platforms for disease management such as diabetes....
...In November, S&N paid $780m for Texas-based Healthpoint Biotherapeutics, in a move that gave the group a foothold in the $1bn-a-year market for bioactive wound care, where treatments derived from proteins...
...The division, which earns about one-quarter of S&N’s revenues, has seen solid growth over the past few years following the rise of diabetes-related ulcers and bedsores....
...He added that the company is not relying on its own internal R&D, but that it will look to add to its portfolio to advance certain types of therapies such as diabetes drugs....
...But Ms Nooyi insists that she is not giving up on nutrition, emphasising that the company cares both about food that is fun and good for customers. “This is an ‘and’ game, not an ‘or’ game,” she says....
International Edition